Travere Therapeutics (TVTX) Enterprise Value (2013 - 2026)

Travere Therapeutics has reported Enterprise Value for 14 years, with the latest figure at -$78.4 million in Q1 2026.

• For the quarter ending Q1 2026, Enterprise Value fell 26.6% year-over-year to -$78.4 million; the trailing twelve-month figure through Mar 2026 stood at -$78.4 million (down 26.6% YoY), and the FY2025 full-year result was -$93.0 million, down 58.94% from the prior year.
• Enterprise Value for Q1 2026 stood at -$78.4 million, up from -$93.0 million in the prior quarter.
• The five-year high for Enterprise Value was -$32.3 million in Q2 2024, with the low at -$256.6 million in Q1 2022.
• Historically, Enterprise Value has averaged -$98.5 million across 5 years, with a median of -$75.2 million in 2025.
• Annual changes were most pronounced in 2024 — Enterprise Value soared 74.76% — and 2025, when it tumbled 204.68%.
• Travere Therapeutics' Enterprise Value stood at -$61.7 million in 2022, then grew by 5.69% to -$58.2 million in 2023, then dropped by 0.62% to -$58.5 million in 2024, then slumped by 58.94% to -$93.0 million in 2025, then increased by 15.77% to -$78.4 million in 2026.
• The last three Enterprise Value figures came in at -$78.4 million (Q1 2026), -$93.0 million (Q4 2025), and -$110.9 million (Q3 2025), per Business Quant data.